The miraculous ability of injected plasmid DNA to induce an immune response against the encoded protein could simplify vaccine formulations for infectious diseases, For cancer, DNA plasmids provide the opportunity to design and test efficacy of potential tumour antigens, and to direct these antigens into relevant pathways of antigen processing. The exciting possibility for vaccinating against cancer is now on the agenda, The days of crude vaccines for use against infectious diseases are clearly numbered. Molecular biology and peptide technology have allowed identification and synthesis of relevant epitopes which should lead to a rational design of reproducible vaccines. In addition, our understanding of the way in which antigens are presented to the immune system is incTeasing to the point where we may be able to promote cytotoxic T -ceIl responses. However, formulation and delivery of vaccines still present problems, particularly for the Third World where the majority of infectious diseases flourish.
DNA vaccines against influenza have been producer!'. If these simple and inexpensive DNA vaccines can be shown to be effective, this approach will solve many of the difficulties of vaccine formulation. A further advantage is that, since virus sequences from conserved regions not normally exposed to the immune system can be placed into the DNA plasmid, it appears possible to generate cross-reactive immunity which will act against a range of influenza viruses. This would allow the vaccine to remain effective even in the face of mutational changes in the haemagglutinin sequences. The influenza virus model has already demonstrated that DNA plasmids can induce protective immunity, with generation of cytotoxic T ceIls and antibodies, and early studies on other infectious organisms such as malaria are also showing promise.
The opportunity to attack cancer by vaccination is more difficult for many reasons, although molecular definition of tumour antigens is bringing the possibility closer. For viraIly induced cancers, vaccination against virus would obviously protect against the subsequent cancer, and for viruses such as Epstein-Barr virus and hepatitis virus, candidate vaccines are already being tested. Again, there is a possibility of using the DNA vaccine approach for these viruses.
However, for the majority of cancers, tumour antigens are more subtle and less easily recognized by the immune system. Another disadvantage is that vaccination usuaIly would have to be carried out in the presence of residual tumour. Encouraging preliminary results are already available for carcinoembryonic antigen (CEA) which is expressed by several tumours. Induction of protective immunity against colonic carcinoma by vaccination with DNA encoding CEA has been achieved in mice". Interestingly, immunity could be promoted by adding in cytokine-encoding plasmids. For B-cell tumours, idiotypic protein vaccination is known to generate protective immunity, but, since idiotypic immunoglobulin differs for each patient, the difficulty has been in the requirement for 'personal' vaccines. The use of DNA plasmids encoding idiotypic protein has simplified the approach to the point where a vaccine can be prepared in 2-3 weeks". Encouraging results on induction of anti-idiotypic response in a model system have led to a small clinical trial. Addition of cytokine-encoding vectors again provides a means of stimulating appropriate immune pathways to generate effective anti-tumour immunity, which may be necessary in patients with disease.
FinaIly, melanoma provides a cancer with candidate antigens for generation of immunity. Stimulation of natural immunity may require only delivery of a suitable cytokine, and transfer of cytokine genes into tumour cells (ex vivo) should ensure that cytokines will be delivered to the tumour site on re-infusion: the effects of this approach are being assessed in a clinical trial. Other possibilities for attacking tumour include insertion of the HSVtk gene which renders the transfected cell susceptible to ganeiclovir, and the hope there is that death of transfected cells would encourage death of neighbouring tumour cells via a bystander effect. There is also some indication that dying tumour cells may be capable of generating an immune response against the tumour.
Clearly, there are interesting times ahead in the development of vaccines against cancer, and we shaIl soon need the courage of Jenner (whose bicentenary we celebrate next year) and James Phipps to test clinical efficacy of the options presented by genetic manipulation.
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